Could Endometriosis Be Affecting Your Fertility?

June is World Infertility Awareness Month. Infertility affects millions globally, yet misconceptions persist about its prevalence and causes. It's a global health issue defined by the WHO as the inability to achieve pregnancy after 12 months of regular, unprotected intercourse.

One major cause of infertility is endometriosis. This condition, where endometrial-like tissue grows outside the uterus, affects up to 50% of women with infertility.

Let's shed light on endometriosis and empower individuals with knowledge and resources to navigate their fertility journey. Together, we can break the stigma surrounding infertility and foster a supportive community. Gesynta Pharma is dedicated to the development of better treatments for endometriosis patients.


Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II for endometriosis, while GS-073 is ready to enter clinical phase I for chronic inflammatory pain.